Maraviroc Prevents HCC Development by Suppressing Macrophages and the Liver Progenitor Cell Response in a Murine Chronic Liver Disease Model

Maraviroc Prevents HCC Development by Suppressing Macrophages and the Liver Progenitor Cell Response in a Murine Chronic Liver Disease Model

Maraviroc (MVC), a CCR5 antagonist, reduces liver fibrosis, injury and tumour burden in mice fed a hepatocarcinogenic diet, suggesting it has potential as a cancer therapeutic. We investigated the effect of MVC on liver progenitor cells (LPCs) and macrophages as both have a role in hepatocarcinogene...

Full description

Bibliographic Details
Main Authors: Adam M. Passman, Robyn P. Strauss, Sarah B. McSpadden, Megan Finch-Edmondson, Neil Andrewartha, Ken H. Woo, Luke A. Diepeveen, Weihao Zhao, Joaquín Fernández-Irigoyen, Enrique Santamaría, Laura Medina-Ruiz, Martyna Szpakowska, Andy Chevigné, Hyerin Park, Rodrigo Carlessi, Janina E. E. Tirnitz-Parker, José R. Blanco, Roslyn London, Bernard A. Callus, Caryn L. Elsegood, Murray V. Baker, Alfredo Martínez, George C. T. Yeoh, Laura Ochoa-Callejero
Format: Article
Language:English
Published: MDPI AG 2021-09-01
Series:Cancers
Subjects:
CCL5 chemokine
hepatocellular carcinoma
liver progenitor cells
macrophages
Maraviroc
Online Access:https://www.mdpi.com/2072-6694/13/19/4935

Internet

https://www.mdpi.com/2072-6694/13/19/4935

Similar Items